※一部利用できない機能があります
| 1.
図書 |
図書
|
[edited by] Douglas L. Mann, G. Michael Felker
|
||||
| 2.
図書 |
図書
|
by Hooshang Bolooki
|
||||
| 3.
図書 |
図書
|
With a foreword by John H. Gibbon, Jr
|
||||
| 4.
図書 |
図書
|
[by] Pamela F. Prior
|
||||
| 5.
論文 |
論文
|
Matsuo, Shinro ; Nakajima, Kenichi ; Nakata, Tomoaki
概要:
Background:Although there are several known prognostic determinants in heart failure (HF), individual risk profiles can
…
vary, in particular between ischemic and non-ischemic HF background. This study investigated the difference in prognostic efficacy of cardiac 123I-meta-iodobenzylguanidine (MIBG) imaging between the 2 etiologies.Methods and Results:All 1,322 patients with HF were enrolled and followed up at most after 10 years. The HF patients were divided into 2 groups: an ischemic group (n=362) and non-ischemic group (n=960), and Cox proportional hazards model was used for data analysis. During 10 years of follow-up, 296 (22.4%) of 1,322 patients died; the mortality rates were 21.8% and 22.6% for the ischemic and non-ischemic groups, respectively. The ischemic group had greater prevalence of sudden death and lethal acute myocardial infarction, and the non-ischemic group had a higher rate of pump failure death. On multivariate Cox proportional hazards analysis using categorized variables, in the ischemic group, delayed heart-to-mediastinum ratio (HMR; P<0.0001), age (P=0.0002) and LVEF (P=0.03) were the independent significant predictors of lethal events. In the non-ischemic group, delayed HMR (P<0.0001), NYHA class (P<0.0001) and age (P<0.0001) were significant determinants of lethal outcome.Conclusions:Cardiac MIBG imaging has nearly identical prognostic value in both ischemic and non-ischemic HF, independent of cause of cardiac death. (Circ J 2016; 80: 435–441)
続きを見る
|
||||
| 6.
論文 |
論文
|
Matsuo, Shinro ; Nakajima, Kenichi ; Nakata, Tomoaki
概要:
Background:Although there are several known prognostic determinants in heart failure (HF), individual risk profiles can
…
vary, in particular between ischemic and non-ischemic HF background. This study investigated the difference in prognostic efficacy of cardiac 123I-meta-iodobenzylguanidine (MIBG) imaging between the 2 etiologies.Methods and Results:All 1,322 patients with HF were enrolled and followed up at most after 10 years. The HF patients were divided into 2 groups: an ischemic group (n=362) and non-ischemic group (n=960), and Cox proportional hazards model was used for data analysis. During 10 years of follow-up, 296 (22.4%) of 1,322 patients died; the mortality rates were 21.8% and 22.6% for the ischemic and non-ischemic groups, respectively. The ischemic group had greater prevalence of sudden death and lethal acute myocardial infarction, and the non-ischemic group had a higher rate of pump failure death. On multivariate Cox proportional hazards analysis using categorized variables, in the ischemic group, delayed heart-to-mediastinum ratio (HMR; P<0.0001), age (P=0.0002) and LVEF (P=0.03) were the independent significant predictors of lethal events. In the non-ischemic group, delayed HMR (P<0.0001), NYHA class (P<0.0001) and age (P<0.0001) were significant determinants of lethal outcome.Conclusions:Cardiac MIBG imaging has nearly identical prognostic value in both ischemic and non-ischemic HF, independent of cause of cardiac death. (Circ J 2016; 80: 435–441)<br />出版者照会後に全文公開
続きを見る
|
||||
| 7.
論文 |
論文
|
Matsuo, Shinro ; Nakajima, Kenichi ; Nakata, Tomoaki ; 松尾, 信郎 ; 中嶋, 憲一
概要:
Background:Although there are several known prognostic determinants in heart failure (HF), individual risk profiles can
…
vary, in particular between ischemic and non-ischemic HF background. This study investigated the difference in prognostic efficacy of cardiac 123I-meta-iodobenzylguanidine (MIBG) imaging between the 2 etiologies.Methods and Results:All 1,322 patients with HF were enrolled and followed up at most after 10 years. The HF patients were divided into 2 groups: an ischemic group (n=362) and non-ischemic group (n=960), and Cox proportional hazards model was used for data analysis. During 10 years of follow-up, 296 (22.4%) of 1,322 patients died; the mortality rates were 21.8% and 22.6% for the ischemic and non-ischemic groups, respectively. The ischemic group had greater prevalence of sudden death and lethal acute myocardial infarction, and the non-ischemic group had a higher rate of pump failure death. On multivariate Cox proportional hazards analysis using categorized variables, in the ischemic group, delayed heart-to-mediastinum ratio (HMR; P<0.0001), age (P=0.0002) and LVEF (P=0.03) were the independent significant predictors of lethal events. In the non-ischemic group, delayed HMR (P<0.0001), NYHA class (P<0.0001) and age (P<0.0001) were significant determinants of lethal outcome.Conclusions:Cardiac MIBG imaging has nearly identical prognostic value in both ischemic and non-ischemic HF, independent of cause of cardiac death. (Circ J 2016; 80: 435–441)
続きを見る
|
||||
| 8.
論文 |
論文
|
長井, 英夫 ; Nagai, Hideo
概要:
金沢大学附属病院<br />平成10年度に超音波心筋組織診断が可能なように市販の超音波心エコー装置に改良を加え,アドリアマイシンを含むanthracycline系抗がん剤投与患者の心筋組織性状診断をIBを用いて行い,anthracyclin
…
e系抗がん剤投与患者においては従来の心エコーで評価した心機能指標が正常にも関わらずIB指標が異常である症例がみられることを第63回日本循環器学会学術集会(1999年3月27〜29日,東京)で発表した.平成11年度は比較的単一のプロトコールで治療されている非ホジキンリンパ腫患者を対象に心筋組織性状診断を行い,アドリアマイシン投与量とIB指標,従来の心エコー指標を比較した.未治療群(C群)とアドリアマイシン治療群(L群,DXR総投与量≦200mg/m^2;M群,≦400mg/m^2;H群>400mg/m^2)において各群間で従来の心エコー指標には差がみられなかったが,IBの心周期変動(CV-IB)はアドリアマイシン総投与量の増加により低下し,C群,L群に比しH群で有意に低値であった.以上よりIBの解析により早期にアドリアマイシンによる心筋障害が検出できる可能性が示唆された.上記の要旨は第15回北陸心筋代謝研究会(2000年2月26日,金沢)において発表した.現在論文化の準備を進めている.<br />研究課題/領域番号:10770305, 研究期間(年度):1998 – 1999<br />出典：「超音波心筋組織診断によるアドリアマイミン心臓障害の評価」研究成果報告書 課題番号10770305（KAKEN：科学研究費助成事業データベース（国立情報学研究所））（https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-10770305/)を加工して作成
続きを見る
|
